The aim of this study was to evaluate the prevalence of IgG, IgA and IgM anti‐β2‐GPI
antibodies in anti‐phospholipid syndrome (APS), and to establish the clinical significance of …

Although the physiological role of beta2‐glycoprotein I (B2GPI) is unknown, in vitro evidence
indicates that B2GPI may be a natural anticoagulant. In this study we have examined …

Abstract β2 Glycoprotein-I (β2GPI), a plasma component with in vitro anticoagulant
properties, has been identified as a cofactor for the binding of some antiphospholipid …

Introduction Currently available clinical assays to detect antiphospholipid antibodies (aPL)
test for IgG and IgM antibodies to cardiolipin (aCL) and β2-glycoprotein I (aβ2GPI). It has …

Abstract “Antiphospholipid” autoantibodies are associated with arterial and venous
thrombosis, recurrent fetal loss, and thrombocytopenia. At present, the best-characterized …

Recurrent thrombosis and miscarriages are the main clinical manifestations of
antiphospholipid syndrome (APS). Although most patients display both clinical signs, some …

The importance of testing for anticardiolipin antibodies (aCL) in the diagnosis of
antiphospholipid syndrome (APS) in patients with thrombosis has recently been challenged …

From its discovery in the early 60s till the beginning of the 90s, there was not much interest
in plasma protein β2-glycoprotein I (β2-GPI). The finding that β2-GPI acts as an essential …

Objective It has been suggested that only antibodies against domain 1 (D1) of β2‐
glycoprotein I (β2GPI) are pathogenic and diagnostic. The role of antibodies against other …

Beta-2 glycoprotein I (β2GPI) is the principal target of autoantibodies in the antiphospholipid
syndrome (APS). It is abundant in human plasma and shares high homology between …